|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-11-15
|
|
pubmed:abstractText |
This randomized, double-blind, placebo-controlled study was designed to assess whether the addition of the matrix metalloproteinase (MMP) inhibitor BMS-275291 to combined paclitaxel and carboplatin chemotherapy had an adverse impact on expected tumor response or had significant toxicity, especially arthrotoxicity, in patients with advanced non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
pubmed-author:ArnoldAndrewA,
pubmed-author:DavisMaryM,
pubmed-author:DouillardJean-YvesJY,
pubmed-author:HumphreyJeffreyJ,
pubmed-author:OttawayJonJ,
pubmed-author:Paz-AresLuisL,
pubmed-author:PeschelChristianC,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrancesF,
pubmed-author:SmylieMichaelM,
pubmed-author:TonatoMaurizioM,
pubmed-author:TuDongshengD,
pubmed-author:VoiMaurizioM,
pubmed-author:VreckemAnne VanAV,
pubmed-author:YoungKatherineK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
361-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15541822-Administration, Oral,
pubmed-meshheading:15541822-Aged,
pubmed-meshheading:15541822-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15541822-Carboplatin,
pubmed-meshheading:15541822-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15541822-Double-Blind Method,
pubmed-meshheading:15541822-Female,
pubmed-meshheading:15541822-Humans,
pubmed-meshheading:15541822-Imidazoles,
pubmed-meshheading:15541822-Infusions, Intravenous,
pubmed-meshheading:15541822-Lung Neoplasms,
pubmed-meshheading:15541822-Male,
pubmed-meshheading:15541822-Matrix Metalloproteinases,
pubmed-meshheading:15541822-Middle Aged,
pubmed-meshheading:15541822-Organic Chemicals,
pubmed-meshheading:15541822-Paclitaxel,
pubmed-meshheading:15541822-Placebos
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
|
|
pubmed:affiliation |
Centre Rene Gauducheau, Nantes, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase II
|
